Objective: To determine the effects of dietary consumption of Bi®dobacterium lactis (strain HN019, DR10 TM ) on natural immunity. Design: A randomized, double blind, placebo-controlled clinical trial. Setting:: Janeway Medical Centre, Memorial University, St Johns, Newfoundland. Subjects: Twenty-®ve healthy elderly volunteers (median age 69 y; range 60 ± 83 y). Interventions: Twelve control subjects consumed 180 ml low-fatalow-lactose milk twice daily for a period of 6 weeks; 13 test subjects consumed milk supplemented with 1.5610 11 colony-forming units of B. lactis twice daily. Indices of natural immunity, including interferon production, phagocytic capacity and phagocyte-mediated bactericidal activity, were determined via peripheral blood at 0, 3, 6 and 12 weeks post-trial commencement. Results: Subjects who consumed milk containing B. lactis for 6 weeks produced signi®cantly enhanced levels of interferon-alpha, upon stimulation of their peripheral blood mononuclear cells in culture, in comparison to the placebo control group who received milk alone. There were also signi®cant increases in polymorphonuclear cell phagocytic capacity among test group subjects, following consumption of milk supplemented with B. lactis, while individuals who consumed B. lactis-supplemented milk or milk alone showed enhanced phagocytemediated bactericidal activity.
Introduction
Lactic acid bacteria (LAB) are among the most numerous of the commensal micro¯ora inhabiting the human large intestine. LAB are generally thought to play an important role in the maintenance of gut homeostasis and are bene®cial to health (Fuller and Gibson, 1995) . Certain strains of LAB, most notably lactobacilli and bi®dobacteria, are also predominant in fermented foodstuffs, particularly dairy products such as yoghurt and cheese. Dietary intake of fermented food products containing LAB has been suggested to confer a range of health bene®ts to consumers, including improved digestion and alleviation of constipation, increased uptake of dietary minerals, reduction in blood cholesterol levels and enhanced protection from tumours (Fuller and Gibson, 1995; Marteau and Rambaud, 1993) . There are now moves to isolate and characterize novel strains of LAB with probiotic activities, such that they might be incorporated into health-promoting functional foods .
Over the last decade, there have been several studies to indicate that some strains of LAB, including those isolated from dairy food products, can enhance natural immunity when included in dietary formulations (De Simone et al, 1991; Gill, 1998) . Health claims for dietary probiotic bacteria such as LAB, via enhancement of natural immune function, have come mainly from laboratorybased trials using rodent models. The immune-enhancing effects include increased non-speci®c phagocytic activity against bacteria (Perdigon et al, 1986; Gill et al, 1999) and enhanced myeloid and lymphoid cell cytokine production (Vesley et al, 1985; Keller et al, 1994; Kitizawa et al, 1994 Kitizawa et al, , 1996 . Studies in humans have also indicated that dietary LAB can impart measurable bene®ts on immune performance, including an increase in peripheral blood phagocyte function (Schiffrin et al, 1995; Marteau & Rambaud, 1993; Marteau et al, 1997) , and the enhanced production of interleukins and interferons (Solis-Pereya and Lemmonier, 1993) . Clearly, LAB have the potential to enhance immune function in both animal models and humans, however it is important to corroborate the results of a proven immuneenhancing LAB formulation from animal studies with a controlled clinical trial, in order to verify the formulation's ef®cacy in humans.
Recent studies by our group have identi®ed a number of probiotic LAB strains from dairy products which display immunity-enhancing properties (Gill, 1998; Gill et al, 1999; Prasad et al, 1999) . In particular, Bi®dobacterium lactis (strain HN019, DR10 TM ) has been shown to enhance phagocytic cell function and the production of interferongamma (IFNg) in laboratory animals, and to increase immune-mediated resistance in mice to challenge with a virulent strain of Salmonella typhimurium (Gill, 1998; Gill et al, 1999; Shu et al, 1999) . In the present study, we report the immunomodulatory effects of dietary B. lactis HN019 in healthy elderly subjects. This age group was speci®cally targeted to determine possible immunity-enhancing effects of B. lactis consumption, since natural cellular immune functions are known to decline in the elderly (Makinodan, 1995) , and these individuals therefor have the greatest potential to bene®t from immunity enhancement.
Materials and methods
Preparation of diets Bi®dobacterium lactis HN019 was obtained from the New Zealand Dairy Research Institute Culture Collection (NZDRI, Palmerston North, New Zealand). For experimental purposes, lyophilized bacteria were incorporated into low-fat, low-lactose milk powder (1.5610 11 colony forming units (cfu)a25g powder), which was reconstituted to 180 mL immediately prior to consumption.
Bacteriology
Bacterial cell viability in the test product was determined by culturing on MRSC agar plates . Bi®dobacteria in stool samples were detected using Beerens' medium (Beerens, 1991) and the presence of B. lactis HN019 was con®rmed by RAPD-DNA analysis using a strain-speci®c DNA probe.
Subjects and trial criteria
Twenty-®ve volunteers with a minimum age of 60 y were selected for this study. Prior to commencement of the trial, the selection criteria included general good health and mobility, with no recent history of acute or chronic debilitating illness, no record of milk-product intolerance, and agreement to avoid potentially con¯icting nutritional or vitamin supplements. Subjects were randomly assigned to two groups. Control group subjects (n 12, 4 male, 8 female; median age 67 y; range 60 ± 75 y) consumed 180 ml reconstituted milk twice daily. Test group subjects (n 13, 3 male, 10 female; median age 70 y; ; range 62 ± 83 y) consumed 180 ml reconstituted milk containing 1.5610 11 cfu live B. lactis strain HN019 (DR10 TM ) twice daily. All diets were double-blinded. Compliance with the dietary regimes was con®rmed by the subjects over a period of 6 weeks, after which time both dietary regimes were ceased.
Peripheral blood samples were withdrawn from subjects at the commencement of the study (week 0) to provide baseline measurements of immune function, and again at 3, 6 and 12 weeks following commencement of the study. Patients' general health conditions were monitored at each subsequent visit to a registered GP. The study protocol was approved by the Memorial University Human Ethics Committee.
Cell isolation culture and immunological assays
Approximately 15 ml blood was withdrawn from subjects by venipuncture. Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs) were separated using centrifugation over isotonic PolymorphPrep. Cell types were prepared separately and washed via centrifugation in phosphate-buffered saline. Prior to in vitro experimentation, cells were counted (trypan blue dye exclusion) and resuspended to the desired concentration in RPMI 1640 medium supplemented with 10% foetal calf serum.
Production of interferon-alpha (IFNa) was assessed in PBMC cultures. Brie¯y, cells were seeded at 10 6 per well into 24-well tissue culture plates and stimulated for 72 h with 10 mgaml phytohaemagglutinin (PHA; Sigma, USA). Culture supernatants were removed, ®ltered and stored at 7 70 C. IFNa was subsequently measured in thawed supernatants using a commercial enzyme immunoassay (Biosource International, Canada). Results were calculated as pg IFNa per ml culture supernatant, against a standard curve generated using recombinant human IFNa.
Phagocytic capacity and bactericidal activity were assessed in PMN cultures. Brie¯y 2.5610 6 PMNs were added to siliconized glass tubes in RPMI supplemented with human plasma (from a healthy donor). Approximately 10 8 log-phase Staphylococcus aureus were added to the tubes, and incubated for 20 min at 37 C, with gentle agitation. Phagocytosis of bacteria and bactericidal activity were determined by direct microscopy and cfu counts, respectively. Data were expressed as percentage cells showing phagocytic capacity and percentage of bacteria killed following phagocytosis, respectively, for each cell preparation.
Statistical analyses
Data were initially compared between test (B. lactis-consuming) and control (milk alone) groups by two-sample ttests or one-way analysis of variance (ANOVA) to detect between-group effects of treatment at each time point, and between each of the four time points of the trial (weeks 0, 3, 6 and 12) by repeated measures ANOVA to detect within-groups differences over time. Signi®cant differences in the means between pairs of data were identi®ed by Tukey's post-hoc test. Where large variances existed within a single group, data were re-expressed as a percentage relative to the baseline (pre-treatment) value of 100% for that response. In all cases, a probability value of`0.05 was considered suf®cient to reject the null hypothesis.
Results

Clinical results
All patients complied with the dietary regimes for the designated 6 weeks, and complete immunological analyses were undertaken on these subjects at weeks 0, 3, 6 and 12 following the commencement of the trial. No digestive problems or dietary sensitivities were recorded among the subjects, and no adverse general health problems were reported. The viability of B. lactis in the test product was con®rmed by culturing on MRSC agar plates, and was found to be consistently above 95%. The ability of B. lactis HN019 to colonize the gut was con®rmed by RAPD-DNA analysis using a strain-speci®c DNA probe; results con®rmed the presence of B. lactis HN019 in stool samples of test subjects at post-but not pre-trial time points (data not shown). At the commencement of the trial (week 0) there were no signi®cant differences between test and control Effects of supplementation with B. lactis on mitogenstimulated interferon secretion Subjects consuming milk supplemented with B. lactis showed signi®cantly enhanced production of IFNa at the week 6 sampling point, in comparison to the control group subjects who consumed milk alone for the same period of time (P 0.036; Figure 1 ). Among the test group subjects, production of IFNa was signi®cantly higher after 6 weeks consumption of B. lactis-supplemented milk than at the beginning of the trial (week 0), P 0.037.
Effects of supplementation with B. lactis on PMN cell function Subjects who consumed milk supplemented with B. lactis showed signi®cantly enhanced phagocytic capacity, in comparison to the placebo group who received milk alone (Figure 2 ). While the control group consuming milk alone showed little overall change in phagocytic activity relative to the baseline (week 0) level, the test group consuming milk supplemented with B. lactis showed signi®cant increases in activity 6 and 12 weeks following commencement of the trial, in comparison to their baseline measurements at week 0 (Figure 2) . Subjects who consumed milk supplemented with B. lactis showed signi®cantly higher bactericidal activity at the 3, 6 and 12 week sampling points compared to the baseline measurement of the same group (week 0; Figure  3 ). In addition, there was a signi®cant increase in bactericidal activity over time among the control group (those receiving milk alone), where activity was also higher at 3, 6 and 12 week time points compared to the corresponding week 0 time point for that group (Figure 3 ). There were no signi®cant differences in bactericidal activity between test and control groups.
Discussion
The use of milk products, and milk-associated probiotic bacteria, has been proposed as the basis for developing Figure 2 Effect of dietary consumption of milk, or milk supplemented with B. lactis, on PMN cell phagocytic capacity in healthy elderly subjects. Individuals consumed reconstituted low-fat milk powder, or milk supplemented with B. lactis, for a 6 week period. Phagoctyic capacity was assessed as the number of PMN cells showing phagocytic activity. Data represent percentage changes in phagocytic capacity in relation to the baseline response at week 0, calculated for each individual of each group. Results are presented as mean percentage changes for each group at each time point, AE s.e.m. *Signi®cantly higher increase in phagocytic capacity of PMN cells among subjects who consumed milk B. lactis, in comparison to either the control group subjects at the same time-points, or in comparison to the same individuals at the week 0 time point (P`0.05). Open bars: milk alone; solid bars: milk supplemented with B. lactis. lactis, on interferon production in healthy elderly subjects. Individuals consumed reconstituted low-fat milk powder, or milk supplemented with B. lactis, for a 6 week period. Production of interferon-alpha (IFNa) was determined as mean unitsaml AE s.e.m. produced by mitogenstimulated PBMCs of subjects from each group. *Signi®cantly higher production of IFNa among subjects who consumed milk B. lactis for 6 weeks, in comparison to either the control group subjects at the same timepoint, or in comparison to the same individuals at the week 0 time point (P`0.05). Open bars: milk alone; Solid bars: milk supplemented with B. lactis.
Immune enhancement by B lactis K Arunachalam et al immune-enhancing functional foods (Gill, 1998; Gill, 2000) . This is particularly important for healthy subjects among demographic groups who, due to intrinsic or extrinsic in¯uences, may be at increased risk of disease. Aging is a process known to cause de®ciency of the immune system (Chandra, 1997) , which may predispose individuals to an increased incidence of systemic diseases, including microbial infections and malignancies. For this reason, our current study focussed on the ability of a de®ned strain of B. lactis (HN019) to modulate natural immunity in health elderly subjects. Dietary inclusion of B. lactis was shown to impart a number of enhancing effects on the natural immune system, including an increase in secretion of interferon-alpha (IFNa) by mononuclear cells, and enhanced PMN cell phagocytic activity.
Many previous studies in animal models and human subjects have shown that LAB can enhance the innate immune function of phagocytic cells (granulocytes and monocyteamacrophages), both following dietary inclusion in vivo and via in vitro exposure of isolated leucocytes to LAB (Perdigon & Alvarez, 1992; Perdigon et al, 1986; De Simone et al, 1986; Schiffrin et al, 1995; Marteau & Rambaud, 1983; Marteau et al, 1997) . While the precise mechanism by which LAB enhance phagocyte function remains uncertain, it is known that live LAB preparations generally stimulate phagocytes better than killed bacteria (De Simone et al, 1986; Miettinen et al, 1996) and that there are strain differences in the quality of immune enhancement (Miettinen et al, 1996; Gill, 1998) . The strain of B. lactis used in the present study (HN019) has been shown to be a potent modulator of phagocyte function in mice (Gill, 1998; Gill et al, 1999) , and the test product used in this study contained high B. lactis viability on reconstitution.
Previous studies have shown that certain strains of probiotic LAB are potent modulators of natural (nonlymphoid) cellular immune function in humans, including B. bi®dum strain Bb12 and Lactobacillus acidophilus strain La1 (Schiffrin et al, 1995) . In the present study, the major immunological effects observed among subjects consuming B. lactis HN019 were an elevation in PMN cell phagocytic capacity, and an enhanced production of IFNa by mononuclear cells in culture. In light of these results, it appears that B. lactis HN019 is a strain which is able to enhance important non-lymphoid host defence mechanisms. It is considered that an increase in systemic phagocyte function, following consumption of LAB, will impart health bene®ts primarily by enhancing a subject's capacity to ®ght microbial infection, such as gastro-intestinal (GI)-tract pathogens and secondary-infection bacteria and mycoses (Gill, 1998) . Previous studies have indicated that dietary consumption of some strains of LAB can signi®cantly enhance host resistance to GI-tract infections, and subsequently reduce clinical recovery times Majamaa et al, 1995; Saxelin, 1997) . The strain of B. lactis used here (HN019) has recently been shown to enhance phagocytic cell function and increase resistance in mice to infection with Salmonella typhimurium (Shu et al, 1999) , further indicating that dietary consumption of probiotic LAB has the potential to offer signi®cant immune-mediated improvements in health.
In the present study, we demonstrated that subjects who consumed milk supplemented with B. lactis had enhanced production of IFNa, in comparison to subjects who received milk alone. Interferon-alpha is produced primarily by stimulated macrophages and natural killer (NK) cells (components of the natural immune system), and is known to have activity against viral infections. Dietary LAB have been shown previously to enhance the production of interferons in both animal models and humans (De Simone et al, 1989 Kishi et al, 1996; Gill, 1998; Gill et al, 1999) , while increased 2-5A synthetatse activity (a marker for IFN production) has been demonstrated in the peripheral blood of human subjects fed live yoghurt cultures (Solis-Pereya & Lemmonier, 1991) . While the direct health bene®ts of increased interferon-producing capacity remain to be proven, it is likely that dietary LAB will contribute to an enhanced capacity of mononuclear phagocytes and NK cells to kill viruses and virally altered targets, including infected cells and oncogenetic malignancies. A recent report has demonstrated that dietary Lactobacillus breves (subspecies coagulans) can enhance virus-induced production of IFNa by PBMCs isolated from healthy human subjects (Kishi et al, 1996) .
It was noteworthy in the present study that time-dependent increases in PMN cell bactericial activity were recorded among both groups of elderly subjects, i.e. those who consumed milk supplemented with B. lactis and those who consumed milk alone. While this result was not anticipated, it is not without precedent, since milk contains a number of immunologically-active proteins that are known to enhance phagocyte function, including a-lactalbumin, b-casein, caseinoglycopeptide and lactoferrina lactoperoxidase (Otani & Futakami, 1994; Otani & Monnai, 1995; Wong et al, 1997) . Furthermore, the results of the present study are consistent with our earlier studies in which mice fed milk-based diets were also found to exhibit enhanced immune function (Gill, unpublished) . These observations con®rm that milk provides not only a biologically relevant vehicle to aid gut colonization by probiotic LAB (Poch & Bezkorovainy, 1988; Gopal & Gill, unpublished) , but can further enhance the immune-enhancing potential of a diary-based product.
In conclusion, the results of the present study have clearly demonstrated that dietary B. lactis can impart measurable bene®ts on natural immune function among healthy elderly subjects. Furthermore, results suggest that there is an additional bene®cial effect on natural immunity if B. lactis is delivered in a milk-based diet, and that a relatively short-term diet (6 weeks) is suf®cient to promote measurable improvements in immune function. Further clinical studies are required to verify that LAB-stimulated enhancement of natural immunity corresponds to a measurable health bene®t among recipients, such as a reduction in the incidence of GI tract microbial infections.
